{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T20:42:40Z","timestamp":1774039360576,"version":"3.50.1"},"reference-count":204,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.critrevonc.2023.103988","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T17:03:45Z","timestamp":1682010225000},"page":"103988","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Clinical and molecular overview of immunotherapeutic approaches for malignant skin melanoma: Past, present and future"],"prefix":"10.1016","volume":"186","author":[{"given":"Raphaelly","family":"Venzel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Clara Paulino","family":"Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larissa Pessoa","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo Vasquez","family":"Dan Lins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1damo Davi Di\u00f3genes","family":"Siena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim Tavares","family":"Mesquita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T\u00e1lita Pollyana","family":"Moreira dos Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nijiro","family":"Nohata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas Coelho Marli\u00e8re","family":"Arruda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helioswilton","family":"Sales-Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marinaldo Pac\u00edfico Cavalcanti","family":"Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.critrevonc.2023.103988_bib1","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat. Med"},{"key":"10.1016\/j.critrevonc.2023.103988_bib2","unstructured":"Amgen. Imlygic (T-VEC): prescribing information. \u3008https:\/\/www.fda.gov\/media\/\u3009 94129\/download (2015)."},{"key":"10.1016\/j.critrevonc.2023.103988_bib3","unstructured":"Amgen. Imlygic (T-VEC): summary of product characteristics. \u3008https:\/\/www.ema\u3009. europa.eu\/en\/documents\/product-information\/imlygic-epar-productinformation_en.pdf (2019)."},{"issue":"15","key":"10.1016\/j.critrevonc.2023.103988_bib4","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-15-1879","article-title":"Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen","volume":"22","author":"Andersen","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.critrevonc.2023.103988_bib5","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","article-title":"Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial","volume":"23","author":"Andtbacka","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103988_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.03246","article-title":"Clinical responses of oncolytic coxsackievirus A21 (V937) in patients with unresectable melanoma","author":"Andtbacka","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103988_bib7","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.03246","article-title":"Clinical responses of oncolytic coxsackievirus A21 (V937) in patients with unresectable melanoma","author":"Andtbacka","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"53","key":"10.1016\/j.critrevonc.2023.103988_bib8","first-page":"855","article-title":"The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma","author":"Anichini","year":"2004","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103988_bib9","doi-asserted-by":"crossref","first-page":"O4","DOI":"10.1186\/1479-5876-13-S1-O4","article-title":"coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib vesus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation \u2013 positive patients with unresectable locally advanced or metastatic melanoma","volume":"13","author":"Ascierto","year":"2015","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.critrevonc.2023.103988_bib10","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103988_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103354","article-title":"Delivery technologies for T cell gene editing: Applications in cancer immunotherapy","volume":"67","author":"Atsavapranee","year":"2021","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.103988_bib12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00262-012-1371-9","article-title":"Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas","volume":"62","author":"Baghdadi","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.103988_bib13","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.immuni.2016.07.008","article-title":"Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8(+) T cell exhaustion","volume":"45","author":"Bengsch","year":"2016","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103988_bib14","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2021.1926759","article-title":"Role of gut microbiome on immunotherapy efficacy in melanoma","volume":"18","author":"Bibb\u00f2","year":"2022","journal-title":"Hum. Vaccin Immunother."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.103988_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000668","article-title":"Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma","volume":"8","author":"Borch","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2023.103988_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002703","article-title":"Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma","volume":"9","author":"Borch","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.103988_bib17","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1586\/era.11.25","article-title":"Therapy for metastatic melanoma: an overview and update","volume":"11","author":"Boyle","year":"2011","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103988_bib18","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103988_bib19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40425-019-0522-3","article-title":"Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition","volume":"7","author":"Buchbinder","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2023.103988_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179431","article-title":"Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy","volume":"12","author":"Charych","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103988_bib21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.suc.2019.09.004","article-title":"Pathology of melanoma","volume":"100","author":"Chopra","year":"2020","journal-title":"Surg. Clin. North Am."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103988_bib22","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1002\/1097-0142(197806)41:6<2456::AID-CNCR2820410654>3.0.CO;2-B","article-title":"Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene","volume":"41","author":"Cohen","year":"1978","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.103988_bib23","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/path.5039","article-title":"Ultraviolet light and melanoma","volume":"244","author":"Craig","year":"2018","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103988_bib24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3390\/cancers14010110","article-title":"Efficacy of neoadjuvant targeted therapy for borderline resectable III B-D or IV stage BRAF V600 mutation-positive melanoma","volume":"14","author":"Czarnecka","year":"2021","journal-title":"Cancers (Basel)."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.103988_bib25","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/annonc\/mdz398","article-title":"Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis","volume":"30","author":"Dafni","year":"2019","journal-title":"Ann. Oncol."},{"issue":"6529","key":"10.1016\/j.critrevonc.2023.103988_bib26","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103988_bib27","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/annonc\/mdr564","article-title":"Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development","volume":"23","author":"Decoster","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103988_bib28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cytogfr.2017.04.001","article-title":"Regulatory T cells as suppressors of anti-tumor immunity: role of metabolism","volume":"35","author":"DeRosa","year":"2017","journal-title":"Cytokine Growth Factor Rev."},{"issue":"26","key":"10.1016\/j.critrevonc.2023.103988_bib29","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1200\/JCO.21.00675","article-title":"Bempegaldesleukin plus nivolumab in first-line metastatic melanoma","volume":"39","author":"Diab","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103988_bib30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00000441-190412740-00001","article-title":"The influence of complicating diseases upon leukemia","volume":"127","author":"Dock","year":"1904","journal-title":"Am. J. Med. Sci"},{"issue":"7","key":"10.1016\/j.critrevonc.2023.103988_bib31","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(18)30254-7","article-title":"MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"19","author":"Dreno","year":"2018","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.103988_bib32","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomized, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.103988_bib33","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s41591-020-1082-2","article-title":"Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i","volume":"26","author":"Dummer","year":"2020","journal-title":"Nat. Med."},{"issue":"13","key":"10.1016\/j.critrevonc.2023.103988_bib34","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.21.01601","article-title":"Randomized phase III trial evaluating spartalizumab plus dabrafenib and trametinib for BRAF V600-Mutant unresectable or metastatic melanoma","volume":"40","author":"Dummer","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103988_bib35","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.103988_bib36","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomized, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.103988_bib37","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1586\/14737140.2015.1074862","article-title":"Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma","volume":"15","author":"Faghfuri","year":"2015","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"15","key":"10.1016\/j.critrevonc.2023.103988_bib38","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.soc.2005.12.008","article-title":"Evaluation of immunotherapy in the treatment of melanoma","author":"Faries","year":"2006","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"10.1016\/j.critrevonc.2023.103988_bib39","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2023.103988_bib40","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1172\/JCI74589","article-title":"Coinhibitory receptor PD-1H preferentially suppresses CD4\u207a T cell-mediated immunity","volume":"124","author":"Flies","year":"2014","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.critrevonc.2023.103988_bib41","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.4049\/jimmunol.0803245","article-title":"PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients","volume":"182","author":"Fourcade","year":"2009","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.103988_bib42","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J. Exp. Med"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.103988_bib43","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1158\/0008-5472.CAN-13-2908","article-title":"PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8+ T cells induced by melanoma vaccines","volume":"74","author":"Fourcade","year":"2014","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103988_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003853","article-title":"Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses","volume":"10","author":"Friedman","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.103988_bib45","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm.4308","article-title":"VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer","volume":"23","author":"Gao","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2023.103988_bib46","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/417281","article-title":"Cancer microenvironment and endoplasmic reticulum stress response","volume":"2015","author":"Giampietri","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.critrevonc.2023.103988_bib47","unstructured":"Gogas H.J., Ribas A., Chesney J., et al.: MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB\u2013IVM1c melanoma (MEL) [abstract]. Presented at European Society for Medical Oncology Congress, Paris, France, September 15\u201321, 2021 (abstr 1037 O)."},{"key":"10.1016\/j.critrevonc.2023.103988_bib48","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2023.103988_bib49","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.e21588","article-title":"The utility of chemotherapy after immunotherapy failure in metastatic melanoma: A multicenter case series","volume":"36","author":"Goldinger","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.103988_bib50","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1158\/1055-9965.EPI-12-1346","article-title":"Dysplastic nevi and melanoma","volume":"22","author":"Goldstein","year":"2013","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.critrevonc.2023.103988_bib51","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103988_bib52","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s40257-017-0292-y","article-title":"MEK inhibitors in the treatment of metastatic melanoma and solid tumors","volume":"18","author":"Grimaldi","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103988_bib53","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s40257-017-0292-y","article-title":"MEK inhibitors in the treatment of metastatic melanoma and solid tumors","volume":"18","author":"Grimaldi","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.critrevonc.2023.103988_bib54","first-page":"1835","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomized, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020"},{"key":"10.1016\/j.critrevonc.2023.103988_bib55","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/annonc\/mdz011","article-title":"Fiveyear survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103988_bib56","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1634\/theoncologist.2019-0438","article-title":"Intratumoral Immunotherapy-Update 2019","volume":"25","author":"Hamid","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2023.103988_bib57","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/pbc.22724","article-title":"Oncolytic virotherapy reaches adolescence","volume":"55","author":"Hammill","year":"2010","journal-title":"Pedia Blood Cancer"},{"key":"10.1016\/j.critrevonc.2023.103988_bib58","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.critrevonc.2023.103988_bib59","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1158\/2159-8290.CD-20-1546","article-title":"Tilsotolimod with ipilimumab drives tumor responses in Anti-PD-1 refractory melanoma","volume":"11","author":"Haymaker","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2023.103988_bib60","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.2147\/OTT.S170385","article-title":"TIM-3, a promising target for cancer immunotherapy","volume":"11","author":"He","year":"2018","journal-title":"Onco Targets Ther."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.103988_bib61","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/cup.14094","article-title":"Talimogene laherparepvec pseudolymphomatous reaction mimicking metastatic melanoma","volume":"48","author":"Henning","year":"2021","journal-title":"J. Cutan. Pathol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.103988_bib62","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.dsi.2014.05.002","article-title":"Keratinocytes regulate the function of melanocytes","volume":"32","author":"Hirobe","year":"2014","journal-title":"Dermatol. Sin."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.103988_bib63","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"New Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2023.103988_bib64","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"New Engl. J. Med"},{"issue":"13","key":"10.1016\/j.critrevonc.2023.103988_bib65","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0952-7915(00)00195-3","article-title":"Immunity against cancer: lessons learned from melanoma","author":"Houghton","year":"2001","journal-title":"Curr. Opin. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.103988_bib66","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41590-022-01141-1","article-title":"A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance","volume":"23","author":"Huang","year":"2022","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103988_bib67","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2023.103988_bib68","article-title":"Metagenomic and metabolomic analyses reveal synergistic effects of fecal microbiota transplantation and anti-PD-1 therapy on treating colorectal cancer","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103988_bib69","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3390\/pharmaceutics14061228","article-title":"The role of toll-like receptor agonists and their nanomedicines for tumor immunotherapy","volume":"14","author":"Huang","year":"2022","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103988_bib70","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2021.1890512","article-title":"Intratumoral therapies and in-situ vaccination for melanoma","volume":"18","author":"Huppert","year":"2022","journal-title":"Hum. Vaccin Immunother."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103988_bib71","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3390\/biomedicines9060607","article-title":"Metabolic interplay between the immune system and melanoma cells: therapeutic implications","volume":"9","author":"Indini","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2023.103988_bib72","first-page":"31257","article-title":"Treatment of advanced melanoma in 2020 and beyond","volume":"20","author":"Jenkins","year":"2020","journal-title":"J. Invest Dermatol."},{"key":"10.1016\/j.critrevonc.2023.103988_bib73","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fonc.2017.00233","article-title":"Biomarkers for response of melanoma patients to immune checkpoint inhibitors: a systematic review","volume":"7","author":"Jessurun","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103988_bib74","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1659096","article-title":"Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors","volume":"8","author":"Kapp","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2023.103988_bib75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067583","article-title":"Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF\/MEK tool combination reduced skin lesions","volume":"8","author":"King","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2023.103988_bib76","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ymeth.2018.11.008","article-title":"Engineering therapeutic bispecific antibodies using CrossMab technology","volume":"154","author":"Klein","year":"2019","journal-title":"Methods"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.103988_bib77","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-15-2667","article-title":"Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy","volume":"22","author":"Kohlhapp","year":"2016","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2023.103988_bib78","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3389\/fonc.2020.00268","article-title":"Current understanding of the mechanisms underlying immune evasion from PD-1\/PD-L1 immune checkpoint blockade in head and neck cancer","volume":"10","author":"Kok","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2023.103988_bib79","first-page":"13","article-title":"Immune checkpoint inhibitor combinations: current efforts and important aspects for success","volume":"45","author":"Kon","year":"2019","journal-title":"Drug Resist Updates Rev. Comment. Antimicrob. Anticancer Chemother."},{"key":"10.1016\/j.critrevonc.2023.103988_bib80","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1200\/JCO.2012.43.7111","article-title":"Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European organisation for research and treatment of cancer melanoma group in metastatic melanoma","volume":"31","author":"Kruit","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103988_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.690499","article-title":"Cell therapy with tils: training and taming T cells to fight cancer","volume":"12","author":"Kumar","year":"2021","journal-title":"Front Immunol."},{"issue":"20","key":"10.1016\/j.critrevonc.2023.103988_bib82","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"New Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103988_bib83","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"New Engl. J. Med"},{"issue":"16","key":"10.1016\/j.critrevonc.2023.103988_bib84","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2023.103988_bib85","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1158\/0008-5472.CAN-13-1506","article-title":"VISTA regulates the development of protective antitumor immunity","volume":"74","author":"Le Mercier","year":"2014","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103988_bib86","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004779","article-title":"Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma","volume":"10","author":"Lee","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103988_bib87","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/1061186X.2018.1440400","article-title":"Development of small-molecule immune checkpoint inhibitors of PD-1\/PD-L1 as a new therapeutic strategy for tumour immunotherapy","volume":"27","author":"Li","year":"2019","journal-title":"J. Drug Target"},{"key":"10.1016\/j.critrevonc.2023.103988_bib88","doi-asserted-by":"crossref","first-page":"876","DOI":"10.18632\/oncotarget.28252","article-title":"Predicting cancer immunotherapy response from gut microbiomes using machine learning models","volume":"13","author":"Liang","year":"2022","journal-title":"Oncotarget"},{"issue":"15","key":"10.1016\/j.critrevonc.2023.103988_bib89","article-title":"Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: primary phase III results from RELATIVITY-047 (CA224-047)","volume":"39","author":"Lipson","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.103988_bib90","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/sj.gt.3301885","article-title":"ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties","volume":"10","author":"Liu","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.critrevonc.2023.103988_bib91","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-3-319-56017-5_3","article-title":"UV-induced molecular signaling differences in melanoma and non-melanoma skin cancer","volume":"996","author":"Liu-Smith","year":"2017","journal-title":"Adv. Exp. Med Biol."},{"key":"10.1016\/j.critrevonc.2023.103988_bib92","first-page":"133","article-title":"Follow-up analysis of MASTERKEY-265 Phase 1b (ph1b) trial of talimogene laherparepvec (T-VEC) in combination (combo) with pembrolizumab (pembro) in patients (pts) with unresectable stage IIIB\u2013IVM1c melanoma (MEL)","volume":"32","author":"Long","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.critrevonc.2023.103988_bib93","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N. Engl. J. Med"},{"issue":"7","key":"10.1016\/j.critrevonc.2023.103988_bib94","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2017.74.1025","article-title":"Long-term outcomes in patients with BRAFV600-mutant metastatic melanoma who received dabrafenib combined with trametinib","volume":"36","author":"Long","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.103988_bib95","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/cup.13332","article-title":"Panniculitis in a patient with pathologic complete response to talimogene laherparepvec treatment for recurrent, in-transit melanoma","volume":"45","author":"Long","year":"2018","journal-title":"J. Cutan. Pathol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103988_bib96","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.2217\/fon-2019-0666","article-title":"AM. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma","volume":"16","author":"Luke","year":"2020","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2023.103988_bib97","first-page":"68","article-title":"BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients","volume":"22","author":"Mackiewicz","year":"2018","journal-title":"Contemp. Oncol. (Pozn., Pol. )"},{"key":"10.1016\/j.critrevonc.2023.103988_bib98","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0959-8049(02)00479-3","article-title":"Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report","volume":"39","author":"Marchand","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2023.103988_bib99","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2023.103988_bib100","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1158\/1078-0432.CCR-15-2412","article-title":"Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab","volume":"22","author":"Martens","year":"2016","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2023.103988_bib101","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103988_bib102","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103988_bib103","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41591-022-01698-2","article-title":"Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1","volume":"28","author":"McCulloch","year":"2022","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103988_bib104","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1186\/s12885-018-5193-9","article-title":"A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma","volume":"18","author":"McQuade","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2023.103988_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112512","article-title":"Therapeutic potential of CAR T cell in malignancies: a scoping review","volume":"146","author":"Mehrabadi","year":"2022","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.critrevonc.2023.103988_bib106","unstructured":"Melanoma U.K. [Internet]. 2020 melanoma skin cancer report [access on oct 20, 2020]. Avaliable from: \u3008https:\/\/www.melanomauk.org.uk\/2020-melanoma-skin-cancer-report\u3009."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103988_bib107","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00281-018-0703-z","article-title":"Principles of adoptive T cell therapy in cancer","volume":"41","author":"Met","year":"2019","journal-title":"Semin Immunopathol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.103988_bib108","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00439-009-0715-9","article-title":"Genetic risk factors for melanoma","volume":"126","author":"Meyle","year":"2009","journal-title":"Hum. Genet"},{"key":"10.1016\/j.critrevonc.2023.103988_bib109","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Michielin","year":"2019","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103988_bib110","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41416-020-0994-4","article-title":"Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives","volume":"123","author":"Middleton","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103988_bib111","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41416-020-0994-4","article-title":"Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives","volume":"123","author":"Middleton","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103988_bib112","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41416-020-0994-4","article-title":"Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives","volume":"123","author":"Middleton","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2023.103988_bib113","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/s41416-021-01353-6","article-title":"Promises and challenges of adoptive T-cell therapies for solid tumours","volume":"124","author":"Morotti","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"0","key":"10.1016\/j.critrevonc.2023.103988_bib114","first-page":"1","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"0","author":"Muller","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2023.103988_bib115","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1007\/s13555-022-00810-1","article-title":"Modulation of the gut microbiome to enhance immunotherapy response in metastatic melanoma patients: a clinical review","volume":"12","author":"Najmi","year":"2022","journal-title":"Dermatol. Ther."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.103988_bib116","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00262-019-02307-x","article-title":"Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2","volume":"68","author":"Nguyen","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103988_bib117","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.immuni.2015.08.023","article-title":"The cellular and molecular basis of translational immunometabolism","volume":"43","author":"Norata","year":"2015","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103988_bib118","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/imr.12525","article-title":"Immunoregulatory functions of VISTA","volume":"276","author":"Nowak","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.critrevonc.2023.103988_bib119","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/PPO.0000000000000303","article-title":"Mechanisms of resistance to PD-1 and PD-L1 blockade","volume":"24","author":"Nowicki","year":"2018","journal-title":"Cancer J."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.103988_bib120","article-title":"Biological factors behind melanoma response to immune checkpoint inhibitors","volume":"21","author":"Olbryt","year":"2020","journal-title":"Int Mol. Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.103988_bib121","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/jid.2014.533","article-title":"Independent validation of six melanoma risk prediction models","volume":"135","author":"Olsen","year":"2015","journal-title":"J. Invest Dermatol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103988_bib122","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.suc.2019.09.009","article-title":"Principles of immunotherapy in melanoma","volume":"100","author":"Onitilo","year":"2020","journal-title":"Surg. Clin. North Am."},{"issue":"62","key":"10.1016\/j.critrevonc.2023.103988_bib123","doi-asserted-by":"crossref","first-page":"106132","DOI":"10.18632\/oncotarget.22190","article-title":"Immune system and melanoma biology: a balance between immunosurveillance and immune escape","volume":"8","author":"Passarelli","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2023.103988_bib124","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/CMR.0000000000000268","article-title":"BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis","volume":"26","author":"Patel","year":"2016","journal-title":"Melanoma Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.103988_bib125","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2013.04.005","article-title":"Metabolic pathways in immune cell activation and quiescence","volume":"38","author":"Pearce","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2023.103988_bib126","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/1750743X.1.1.19","article-title":"MAGE A3 antigen-specific cancer immunotherapeutic","volume":"1","author":"Peled","year":"2009","journal-title":"Immunotherapy"},{"issue":"10","key":"10.1016\/j.critrevonc.2023.103988_bib127","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1245\/s10434-018-6803-0","article-title":"Talimogene laherparepvec (TVEC) for the treatment of advanced melanoma: a single-institution experience","volume":"25","author":"Perez","year":"2018","journal-title":"Ann. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.103988_bib128","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/01.cco.0000208791.22442.09","article-title":"Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma","volume":"18","author":"Pho","year":"2006","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103988_bib129","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.103988_bib130","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2023.103988_bib131","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3389\/fimmu.2017.00374","article-title":"Editorial: immuno-metabolism in tumor microenvironment","volume":"8","author":"Prado-Garcia","year":"2017","journal-title":"Front Immunol."},{"issue":"8081","key":"10.1016\/j.critrevonc.2023.103988_bib132","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0140-6736(78)91555-6","article-title":"Anaphylactic reaction to intralesional B.C.G","volume":"2","author":"Proctor","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2023.103988_bib133","article-title":"Characteristics of melanoma in elderly","volume":"47","author":"Purim","year":"2020","journal-title":"Rev. Col. Bras. Cir."},{"issue":"22","key":"10.1016\/j.critrevonc.2023.103988_bib134","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","article-title":"Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma","volume":"34","author":"Puzanov","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103988_bib135","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s40425-019-0811-x","article-title":"TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma","volume":"7","author":"Reilley","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103988_bib136","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41591-019-0476-5","article-title":"Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma","volume":"25","author":"Ribas","year":"2019","journal-title":"Nat. Med"},{"key":"10.1016\/j.critrevonc.2023.103988_bib137","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1158\/1538-7445.AM2019-4217","article-title":"Tumor mutational burden (TMB), T cell-inflamed gene expression profile (GEP) and PD-L1 are independently associated with response to pembrolizumab (Pembro) in patients with advanced melanoma in the KEYNOTE (KN)-006 study","volume":"79","author":"Ribas","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2023.103988_bib138","doi-asserted-by":"crossref","first-page":"S868","DOI":"10.1016\/j.annonc.2021.08.1422","article-title":"1037O MASTERKEY-265: a phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB\u2013IVM1c melanoma (MEL)","volume":"32","author":"Ribas","year":"2021","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.103988_bib139","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1158\/2159-8290.CD-21-0425","article-title":"Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma","volume":"11","author":"Ribas","year":"2021","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.103988_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(22)00010-9","article-title":"Nivolumab plus ipilimumab in melanoma brain metastases","volume":"23","author":"Rizzo","year":"2022","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103988_bib141","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Eng. J. Med"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.103988_bib142","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med"},{"issue":"26","key":"10.1016\/j.critrevonc.2023.103988_bib143","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2023.103988_bib144","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label,multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103988_bib145","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/jso.2930090609","article-title":"Risks of BCG intralesional therapy: an experience with melanoma","volume":"9","author":"Robinson","year":"1977","journal-title":"J. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103988_bib146","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1006\/geno.1995.9945","article-title":"The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28","volume":"29","author":"Rogner","year":"1996","journal-title":"Genomics"},{"key":"10.1016\/j.critrevonc.2023.103988_bib147","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2023.103988_bib148","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9582","article-title":"A toll-like receptor agonist to drive melanoma regression as a vaccination adjuvant or by direct tumor application","volume":"35","author":"Royal","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.critrevonc.2023.103988_bib149","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103988_bib150","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s42003-021-02191-1","article-title":"PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efcacy","volume":"4","author":"Sasikumar","year":"2021","journal-title":"Commun. Biol."},{"issue":"17","key":"10.1016\/j.critrevonc.2023.103988_bib151","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2217\/fon-2021-1486","article-title":"STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic\/unresectable BRAF V600-mutant melanoma","volume":"18","author":"Schadendorf","year":"2022","journal-title":"Future Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.103988_bib152","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.immuni.2016.07.009","article-title":"The tumor microenvironment represses T Cell Mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction","volume":"45","author":"Scharping","year":"2016","journal-title":"Immunity"},{"issue":"20","key":"10.1016\/j.critrevonc.2023.103988_bib153","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1158\/0008-5472.CAN-22-0970","article-title":"Inhibition of melanoma cell-intrinsic tim-3 stimulates MAPK-dependent tumorigenesis","volume":"82","author":"Schatton","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2023.103988_bib154","doi-asserted-by":"crossref","DOI":"10.1007\/s40257-020-00509-z","article-title":"Long-term outcomes in BRAF-mutated melanoma treated with combined targeted therapy or immune checkpoint blockade: are we approaching a true cure?","author":"Schummer","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.critrevonc.2023.103988_bib155","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","article-title":"gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma","volume":"364","author":"Schwartzentruber","year":"2011","journal-title":"New Engl. J. Med"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103988_bib156","first-page":"345","article-title":"From melanocytes to melanoma","volume":"16","author":"Shain","year":"2016","journal-title":"Nat. Ver. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.103988_bib157","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3892\/ol.2020.12070","article-title":"Progress of immune checkpoint LAG-3 in immunotherapy (Review)","volume":"20","author":"Shan","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.critrevonc.2023.103988_bib158","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.103988_bib159","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","article-title":"Targeting CDK4 and CDK6: from discovery to therapy","volume":"6","author":"Sherr","year":"2016","journal-title":"Cancer Disco"},{"issue":"12","key":"10.1016\/j.critrevonc.2023.103988_bib160","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/exd.13792","article-title":"CAR-T cell therapy in melanoma: a future success story?","volume":"27","author":"Simon","year":"2018","journal-title":"Exp. Dermatol."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.103988_bib161","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.034272","article-title":"Immunometabolism in cancer at a glance","volume":"11","author":"Singer","year":"2018","journal-title":"Dis. Model Mech."},{"key":"10.1016\/j.critrevonc.2023.103988_bib162","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/107327480901600307","article-title":"Diagnosis and treatment of melanoma brain metastasis: a literature review","volume":"16","author":"Sloan","year":"2009","journal-title":"Cancer Control"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103988_bib163","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/107327481602300104","article-title":"Developments in intralesional therapy for metastatic melanoma","volume":"23","author":"Sloot","year":"2016","journal-title":"Cancer Control"},{"key":"10.1016\/j.critrevonc.2023.103988_bib164","first-page":"357","article-title":"Stereotactic radiosurgery of brain metastases","volume":"60","author":"Specht","year":"2016","journal-title":"J. Neurosurg. Sci."},{"issue":"6575","key":"10.1016\/j.critrevonc.2023.103988_bib165","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1126\/science.aaz7015","article-title":"Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response","volume":"374","author":"Spencer","year":"2021","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.critrevonc.2023.103988_bib166","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/j.cmet.2021.11.010","article-title":"Coenzyme A fuels T cell anti-tumor immunity","volume":"33","author":"St Paul","year":"2021","journal-title":"Cell Metab."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.103988_bib167","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1073\/pnas.0908801107","article-title":"Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis","volume":"107","author":"Stagg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.critrevonc.2023.103988_bib168","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1158\/0008-5472.CAN-12-0420","article-title":"CD73-deficient mice are resistant to carcinogenesis","volume":"72","author":"Stagg","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2023.103988_bib169","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103988_bib170","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.suc.2019.09.013","article-title":"Principles of targeted therapy for melanoma","volume":"100","author":"Sun","year":"2020","journal-title":"Surg. Clin. N. Am."},{"key":"10.1016\/j.critrevonc.2023.103988_bib171","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(20)30726-9","article-title":"Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study","volume":"22","author":"Syeda","year":"2021","journal-title":"Lancet Oncol."},{"issue":"Suppl 3","key":"10.1016\/j.critrevonc.2023.103988_bib172","article-title":"New emerging targets in cancer immunotherapy: the role of VISTA","volume":"4","author":"Tagliamento","year":"2020","journal-title":"ESMO Open."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.103988_bib173","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"12","key":"10.1016\/j.critrevonc.2023.103988_bib174","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","article-title":"Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study","volume":"22","author":"Tawbi","year":"2021","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103988_bib175","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s40425-019-0682-1","article-title":"Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1","volume":"7","author":"Thomas","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2023.103988_bib176","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.731175","article-title":"Targeting Tim-3 in cancer with resistance to PD-1\/PD-L1 blockade","volume":"11","author":"Tian","year":"2021","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103988_bib177","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41392-022-00951-x","article-title":"Engineering strategies to enhance oncolytic viruses in cancer immunotherapy","volume":"7","author":"Tian","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.critrevonc.2023.103988_bib178","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.intimp.2018.08.007","article-title":"Targeting myeloid-derived suppressor cells using all-trans retinoic acid in T melanoma patients treated with Ipilimumab","volume":"63","author":"Tobin","year":"2018","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2023.103988_bib179","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-19-1409","article-title":"Overcoming genetically based resistance mechanisms to PD-1 blockade","volume":"10","author":"Torrejon","year":"2020","journal-title":"Cancer Discov."},{"issue":"26","key":"10.1016\/j.critrevonc.2023.103988_bib180","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103988_bib181","unstructured":"U. S. Food and Drug Administration (FDA). Compilation of CDER New Molecular Entity (NME) Drug and New Biologic Approvals 1985\u20132019. Avaliable from: \u3008https:\/\/www.fda.gov\/media\/135307\/download\u3009."},{"key":"10.1016\/j.critrevonc.2023.103988_bib182","unstructured":"U. S. Food and Drug Administration (FDA). Imlygic (talimogene laherparepvec) prescribing information. 2015. Avaliable from: \u3008https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/cellulargenetherapyproducts\/approvedproducts\/ucm469575.pdf\u3009."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.103988_bib183","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s43018-019-0022-x","article-title":"Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy","volume":"1","author":"Valpione","year":"2020","journal-title":"Nat. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.103988_bib184","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0952-7915(97)80050-7","article-title":"T cell defined tumor antigens","volume":"9","author":"Van den Eynde","year":"1997","journal-title":"Curr. Opin. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103988_bib185","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/07391102.2002.10506853","article-title":"Structural analysis of the inhibition of Cdk4 and Cdk6 by p16(INK4a) through molecular dynamics simulations","volume":"20","author":"Villaca\u00f1as","year":"2012","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.critrevonc.2023.103988_bib186","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejca.2022.09.031","article-title":"Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis","volume":"177","author":"Viscardi","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103988_bib187","first-page":"649","article-title":"Rash after a single injection of T-VEC","volume":"17","author":"Wagenknecht","year":"2019","journal-title":"J. Dtsch Dermatol. Ges."},{"key":"10.1016\/j.critrevonc.2023.103988_bib188","doi-asserted-by":"crossref","first-page":"B196","DOI":"10.1158\/1535-7163.TARG-15-B196","article-title":"Abstract B196: intratumoral administration of IMO-2125, a novel TLR9 agonist, modulates tumor microenvironment and potentiates antitumor activity of anti-PD-1 mAb in a murine colon carcinoma model","volume":"14","author":"Wang","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2023.103988_bib189","doi-asserted-by":"crossref","first-page":"B094","DOI":"10.1158\/2326-6074.CRICIMTEATIAACR15-B094","article-title":"Abstract B094: intratumoral administration of IMO-2125, a novel TLR9 agonist, modulates the tumor microenvironment and exerts systemic antitumor activity alone and in combination with an anti-CTLA-4 mAb","volume":"4","author":"Wang","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2023.103988_bib190","first-page":"1193","article-title":"Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy","volume":"53","author":"Wang","year":"2018","journal-title":"Int J. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.103988_bib191","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2023.103988_bib192","doi-asserted-by":"crossref","first-page":"14846","DOI":"10.1073\/pnas.1407447111","article-title":"Disruption of the immune- checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity","volume":"111","author":"Wang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103988_bib193","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-022-01325-0","article-title":"Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts","volume":"15","author":"Wang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103988_bib194","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2023.103988_bib195","doi-asserted-by":"crossref","first-page":"v533","DOI":"10.1093\/annonc\/mdz255","article-title":"Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III\/IV melanoma: 3-year efficacy and biomarker results from the phase 3 CheckMate 238 trial","volume":"30","author":"Weber","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103988_bib196","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2023.103988_bib197","article-title":"Salvage therapy after failure from anti-PD-1 single agent treatment: A study by the German ADOReg melanoma registry","volume":"37","author":"Weichenthal","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.103988_bib198","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12927","article-title":"T cell receptor therapy against melanoma-Immunotherapy for the future?","volume":"92","author":"Winge-Main","year":"2020","journal-title":"Scand. J. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.103988_bib199","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1089\/jir.2017.0101","article-title":"IL-2 and beyond in cancer immunotherapy","volume":"38","author":"Wrangle","year":"2018","journal-title":"J. Interferon Cytokine Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103988_bib200","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.hoc.2009.03.006","article-title":"The history and future of chemotherapy for melanoma","volume":"23","author":"Yang","year":"2009","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103988_bib201","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.ccell.2018.05.009","article-title":"Non-conventional inhibitory CD4+Foxp3-PD-1hi T cells as a biomarker of immune checkpoint blockade activity","volume":"33","author":"Zappasodi","year":"2018","journal-title":"Cancer Cell."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.103988_bib202","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.21037\/atm-21-491","article-title":"Current status of intralesional agents in treatment of malignant melanoma","volume":"9","author":"Zawit","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.critrevonc.2023.103988_bib203","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2021.09.011","article-title":"Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial","volume":"158","author":"Zimmer","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.103988_bib204","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41379-021-00901-y","article-title":"Analysis of the immune checkpoint V-domain Ig-containing suppressor of T-cell activation (VISTA) in endometrial cancer","volume":"35","author":"Zong","year":"2022","journal-title":"Mod. Pathol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823000768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823000768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:49:47Z","timestamp":1760903387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842823000768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":204,"alternative-id":["S1040842823000768"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.103988","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and molecular overview of immunotherapeutic approaches for malignant skin melanoma: Past, present and future","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.103988","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103988"}}